Literature DB >> 8623914

Stage-specific expression of integrin alphaVbeta3 in neuroblastic tumors.

C L Gladson1, S Hancock, M M Arnold, O M Faye-Petersen, R P Castleberry, D R Kelly.   

Abstract

The ligand specificity of the integrin cell adhesion receptors probably determines the ability of specific integrins to promote tumor cell proliferation and metastasis. Therefore, we compared the expression of integrin alphaVbeta3, a promiscuous receptor that binds with high affinity to numerous cell matrix proteins, with the expression of integrin alphaVbeta5 and the integrin beta 1 subunit (which pairs with multiple alpha subunits) in neuroblastic tumors at various stages of differentiation. Undifferentiated neuroblastoma tumors rapidly invade and metastasize, whereas ganglioneuroblastomas rarely metastasize. Differentiating neuroblastomas are associated with an intermediate prognosis. Paraffin sections of neuroblastic tumors at various stages of differentiation obtained at biopsy from 17 patients were hybridized with antisense integrin subunit-specific alphaV, beta3, beta1, and beta5 riboprobes. All neuroblastic tumors and seven adrenal glands obtained at autopsy were analyzed immunohistochemically with antibodies directed toward the alphaV, beta3, beta1, and beta5 subunits. The alphaV subunit was expressed in neuroblastic tumors independent of the stage of differentiation, although mRNA and protein expression were generally weak in ganglioneuroblastomas, and was also detected in adrenal gland medullae. The beta1 subunit was detected in most neuroblastic tumors independent of the stage of differentiation as well as in adrenal gland medullae. In contrast, the beta3 subunit, which was not expressed in adrenal gland medullae, was expressed at the protein and mRNA levels in undifferentiated neuroblastomas (six of seven and seven of seven, respectively) but was not expressed in neuroblasts or ganglion cells in ganglioneuroblastomas (one case weakly positive out of five). The beta 5 subunit was expressed at the protein (five of five) and mRNA (four of five) levels in the ganglion cells of ganglioneuroblastomas and, although mRNA for this subunit was detectable in undifferentiated tumors, the protein was not detectable. The expression of integrin alphaVbeta3 in undifferentiated neuroblastomas may contribute to the rapid growth of these tumors and their tendency to metastasize.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8623914      PMCID: PMC1861568     

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  32 in total

Review 1.  Biochemical interactions of tumor cells with the basement membrane.

Authors:  L A Liotta; C N Rao; U M Wewer
Journal:  Annu Rev Biochem       Date:  1986       Impact factor: 23.643

2.  Human endothelial cells synthesize and express an Arg-Gly-Asp-directed adhesion receptor involved in attachment to fibrinogen and von Willebrand factor.

Authors:  D A Cheresh
Journal:  Proc Natl Acad Sci U S A       Date:  1987-09       Impact factor: 11.205

3.  Amino acid sequence of the vitronectin receptor alpha subunit and comparative expression of adhesion receptor mRNAs.

Authors:  S Suzuki; W S Argraves; H Arai; L R Languino; M D Pierschbacher; E Ruoslahti
Journal:  J Biol Chem       Date:  1987-10-15       Impact factor: 5.157

4.  Protein sequence of endothelial glycoprotein IIIa derived from a cDNA clone. Identity with platelet glycoprotein IIIa and similarity to "integrin".

Authors:  L A Fitzgerald; B Steiner; S C Rall; S S Lo; D R Phillips
Journal:  J Biol Chem       Date:  1987-03-25       Impact factor: 5.157

5.  Efficient in vitro synthesis of biologically active RNA and RNA hybridization probes from plasmids containing a bacteriophage SP6 promoter.

Authors:  D A Melton; P A Krieg; M R Rebagliati; T Maniatis; K Zinn; M R Green
Journal:  Nucleic Acids Res       Date:  1984-09-25       Impact factor: 16.971

6.  Immunolocalization of monoclonal antibody-defined extracellular matrix antigens in human brain tumors.

Authors:  R D McComb; D D Bigner
Journal:  J Neurooncol       Date:  1985       Impact factor: 4.130

7.  cDNA and amino acid sequences of the cell adhesion protein receptor recognizing vitronectin reveal a transmembrane domain and homologies with other adhesion protein receptors.

Authors:  S Suzuki; W S Argraves; R Pytela; H Arai; T Krusius; M D Pierschbacher; E Ruoslahti
Journal:  Proc Natl Acad Sci U S A       Date:  1986-11       Impact factor: 11.205

8.  Amino acid sequence of the human fibronectin receptor.

Authors:  W S Argraves; S Suzuki; H Arai; K Thompson; M D Pierschbacher; E Ruoslahti
Journal:  J Cell Biol       Date:  1987-09       Impact factor: 10.539

9.  Expression of the beta 6 integrin subunit in development, neoplasia and tissue repair suggests a role in epithelial remodeling.

Authors:  J M Breuss; J Gallo; H M DeLisser; I V Klimanskaya; H G Folkesson; J F Pittet; S L Nishimura; K Aldape; D V Landers; W Carpenter
Journal:  J Cell Sci       Date:  1995-06       Impact factor: 5.285

10.  Detection and characterization of monoclonal antibodies to platelet membrane proteins.

Authors:  P J Newman; R A Kahn; A Hines
Journal:  J Cell Biol       Date:  1981-07       Impact factor: 10.539

View more
  13 in total

1.  Vitronectin expression in differentiating neuroblastic tumors: integrin alpha v beta 5 mediates vitronectin-dependent adhesion of retinoic-acid-differentiated neuroblastoma cells.

Authors:  C L Gladson; C Dennis; T C Rotolo; D R Kelly; J R Grammer
Journal:  Am J Pathol       Date:  1997-05       Impact factor: 4.307

2.  ADAM 23/MDC3, a human disintegrin that promotes cell adhesion via interaction with the alphavbeta3 integrin through an RGD-independent mechanism.

Authors:  S Cal; J M Freije; J M López; Y Takada; C López-Otín
Journal:  Mol Biol Cell       Date:  2000-04       Impact factor: 4.138

Review 3.  The rationale and future potential of angiogenesis inhibitors in neoplasia.

Authors:  G Gasparini
Journal:  Drugs       Date:  1999-07       Impact factor: 9.546

4.  Targeting activated integrin alphavbeta3 with patient-derived antibodies impacts late-stage multiorgan metastasis.

Authors:  Karin Staflin; Joseph S Krueger; Janna Hachmann; Jane S Forsyth; Mihaela Lorger; Sebastian C J Steiniger; Jenny Mee; Cristina Pop; Guy S Salvesen; Kim D Janda; Brunhilde Felding-Habermann
Journal:  Clin Exp Metastasis       Date:  2010-03-12       Impact factor: 5.150

5.  Combinatorial antibody libraries from cancer patients yield ligand-mimetic Arg-Gly-Asp-containing immunoglobulins that inhibit breast cancer metastasis.

Authors:  Brunhilde Felding-Habermann; Richard A Lerner; Antonietta Lillo; Shufei Zhuang; Martin R Weber; Sandra Arrues; Changshou Gao; Shenlan Mao; Alan Saven; Kim D Janda
Journal:  Proc Natl Acad Sci U S A       Date:  2004-11-24       Impact factor: 11.205

6.  Integrin expression regulates neuroblastoma attachment and migration.

Authors:  Amy Meyer; Cynthia M van Golen; Bhumsoo Kim; Kenneth L van Golen; Eva L Feldman
Journal:  Neoplasia       Date:  2004 Jul-Aug       Impact factor: 5.715

7.  Initial characterization of a dually radiolabeled peptide for simultaneous monitoring of protein targets and enzymatic activity.

Authors:  Efrem Mebrahtu; Alexander Zheleznyak; Minjun A Hur; Richard Laforest; Suzanne E Lapi
Journal:  Nucl Med Biol       Date:  2012-11-12       Impact factor: 2.408

Review 8.  Synstatin: a selective inhibitor of the syndecan-1-coupled IGF1R-αvβ3 integrin complex in tumorigenesis and angiogenesis.

Authors:  Alan C Rapraeger
Journal:  FEBS J       Date:  2013-02-24       Impact factor: 5.542

9.  The direct binding of insulin-like growth factor-1 (IGF-1) to integrin alphavbeta3 is involved in IGF-1 signaling.

Authors:  Jun Saegusa; Satoshi Yamaji; Katsuaki Ieguchi; Chun-Yi Wu; Kit S Lam; Fu-Tong Liu; Yoko K Takada; Yoshikazu Takada
Journal:  J Biol Chem       Date:  2009-07-03       Impact factor: 5.157

10.  The role of integrins in cancer and the development of anti-integrin therapeutic agents for cancer therapy.

Authors:  Xinjie Lu; Dong Lu; Mike Scully; Vijay Kakkar
Journal:  Perspect Medicin Chem       Date:  2008-04-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.